GALAPAGOS
Limited liability company
Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium
Company number: 0466.460.429
RLE Antwerp, division Mechelen
(the "**Company**")

Minutes of the Annual Shareholders' Meeting held in Mechelen on 28 April 2026

Bureau

The present meeting to be held at Schaliënhoevedreef 20T, 2800 Mechelen, will be opened at 2:00 p.m. CEST by the Secretary of the meeting.

The meeting is held under the chairmanship of Mr. Jérôme Contamine, Chairman of the Board of Directors of the Company.

The following directors are present: Dr. Jane Griffiths and Mr. Henry Gosebruch.

Mr. Filip Lecoutre, legal counsel of the Company, is designated as Secretary.

Mrs. Annelies Denecker and Mrs. Elien Van Mol are designated as Tellers.

The bureau consists of the Chairman, the Secretary, the present directors and the Tellers.

The Chairman gives the floor to the Secretary.

Secretary's statements

The Secretary states the following:

1. Composition of the meeting

(a) **Shareholders** – The shareholders, whose identity and the number of shares they owned as per the record date (within the meaning of article 7:134, §2 of the Belgian Companies and Associations Code) are mentioned in the attendance list, are present, are represented or have cast their vote by letter. The attendance list was signed by the relevant shareholders or their proxy holder and by the members of the bureau. This attendance list, as well the proxies and voting forms mentioned therein shall remain attached to these minutes.

In a register designated by the Board of Directors, the name of each shareholder who has notified the Company of his / her intention to participate in the shareholders' meeting was noted, as well as the number of shares he or she possessed on the record date and for which he or she indicated to be participating in the shareholders' meeting, and the description of the relevant documents demonstrating that he or she was in possession of the shares on said record date.

A number of proxies was given by the relevant shareholders to the Company's General Counsel who is a member of the Company's staff and a member of the Company's Executive Committee; in each of these cases, specific voting instructions for each agenda item were given by the shareholders, as a result of which no problems relating to potential conflicts of interests between the relevant shareholders and the relevant proxy holder can arise. Two shareholders have designated another proxy holder.

The bureau acknowledges the validity of all proxies and voting forms, including those given by e-mail.

The bureau acknowledges that the delivery by or on behalf of shareholders of any proxies, voting forms or certificates evidencing the ownership of shares as per the record date, is to be considered as a notification by the relevant shareholders of their intention to attend the shareholders' meeting, within the meaning of article 7:134, §2 of the Belgian Companies and Associations Code.

The Secretary states that the Company did not receive written questions from a shareholder.

(b) **Holders of subscription rights** – Three holders of subscription rights issued by the Company (in that capacity) signed up for this meeting. The holders of subscription rights, whose identity and the number of subscription rights he or she possessed on the record date are noted in the attendance list, are present.

(c) **Board members and statutory auditor** – The following Board members are present: Mr. Jérôme Contamine, non-executive independent director and Chairman of the Board of Directors, Mr. Henry Gosebruch, executive director and member of the Executive Committee, and Dr. Jane Griffiths, non-executive independent director. The remaining members of the Board of Directors are represented. The following members of the Executive Committee are present: Mr. Henry Gosebruch, Chief Executive Officer, Fred Blakeslee, General Counsel, and Aaron Cox, Chief Financial Officer. The statutory auditor of the Company, BDO Bedrijfsrevisoren BV, represented by Mrs. Ellen Lombaerts, is present.

2. Agenda of the meeting

The agenda and proposed resolutions of the Annual Shareholders' Meeting are as follows:

1. Acknowledgement and discussion of (a) the annual report of the Board of Directors in relation to the non-consolidated and consolidated annual accounts of the Company for the financial year ended on December 31, 2025, and (b) the report of the statutory auditor in relation to the non-consolidated annual accounts of the Company for the financial year ended on December 31, 2025.

2. Acknowledgement and approval of the non-consolidated annual accounts of the Company for the financial year ended on December 31, 2025, and approval of the allocation of the annual result as proposed by the Board of Directors.

Proposed resolution: The shareholders' meeting resolves to approve the non-consolidated annual accounts of the Company for the financial year ended on December 31, 2025, and the allocation of the annual result as proposed by the Board of Directors.

3. Acknowledgement and discussion of the report of the statutory auditor relating to the consolidated annual accounts of the Company for the financial year ended on December 31, 2025.

4. Acknowledgement and discussion of the consolidated annual accounts of the Company for the financial year ended on December 31, 2025.

5. Acknowledgement and approval of the remuneration report.

Proposed resolution: The shareholders' meeting resolves to approve the remuneration report included in the annual report of the Board of Directors for the financial year ended on December 31, 2025.

6. Release from liability to be granted to the (current and former) members of the Board of Directors, and the statutory auditor for the performance of their respective mandates during the financial year ended on December 31, 2025.

Proposed resolution: The shareholders' meeting resolves, by a separate vote, to release each (current and former) member of the Board of Directors, and the statutory auditor from any liability arising from the performance of their respective mandates during the financial year ended on December 31, 2025.

7. Appointment of Mr. Henry Gosebruch as executive director.

Proposed resolution: Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee of the Board of Directors (hereinafter the “Nomination Committee”), the shareholders' meeting resolves to confirm the appointment by co-optation with effect as per May 12, 2025 (following the resignation of Stoffels IMC BV, permanently represented by Mr. Paul Stoffels, with effect as per the same date) and to appoint Mr. Henry Gosebruch as an executive member of the Board of Directors of the Company, for an additional period of four years, up to and including the closing of the annual shareholders' meeting to be held in 2030 which will have decided upon the financial statements for the financial year ended on December 31, 2029. The shareholders’ meeting also resolves that the mandate of Mr. Henry Gosebruch as a director of the Company will not be remunerated.

8. Appointment of Dr. Jane Griffiths as independent non-executive director.

Proposed resolution: Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee, the shareholders' meeting resolves (a) to confirm the appointment by co-optation with effect as per July 28, 2025 (following the resignation of Mr. Simon Sturge, with effect as per the same date), and to appoint Dr. Jane Griffiths as an independent non-executive member of the Board of Directors of the Company, for an additional period of four years, up to and including the closing of the annual shareholders' meeting to be held in 2030 which will have decided upon the financial statements for the financial year ended on December 31, 2029, and (b) to confirm her mandate as an independent member of the Board of Directors, taking note of the fact that (i) the Board of Directors has determined that Dr. Jane Griffiths meets the independence criteria set forth in article 7:87 of the Belgian Companies and Associations Code, and article 3.5 of the Belgian Corporate Governance Code 2020, (ii) Dr. Jane Griffiths has explicitly declared not to have (and the Board of Directors is not aware of) any connections with the Company or a major shareholder, which would interfere with her independence, and (iii) the Board of Directors has no indication of any element that might call Dr. Jane Griffiths' independence into question. The shareholders' meeting also resolves that the mandate of Dr. Jane Griffiths will be remunerated as provided for non-executive members of the Board of Directors in the Company's remuneration policy and as approved by the shareholders' meeting from time to time.

9. Appointment of Ms. Dawn Svoronos as independent non-executive director.

Proposed resolution: Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee, the shareholders' meeting resolves (a) to confirm the appointment by co-optation with effect as per July 28, 2025 (following the resignation of Mr. Peter Guenter, with effect as per the same date), and to appoint Ms. Dawn Svoronos as an independent non-executive member of the Board of Directors of the Company, for an additional period of four years, up to and including the closing of the annual shareholders' meeting to be held in 2030 which will have decided upon the financial statements for the financial year ended on December 31, 2029, and (b) to confirm her mandate as an independent member of the Board of Directors, taking note of the fact that (i) the Board of Directors has determined that Ms. Dawn Svoronos meets the independence criteria set forth in article 7:87 of the Belgian Companies and Associations Code, and article 3.5 of the Belgian Corporate Governance Code 2020, (ii) Ms. Dawn Svoronos has explicitly declared not to have (and the Board of Directors is not aware of) any connections with the Company or a major shareholder, which would interfere with her independence, and (iii) the Board of Directors has no indication of any element that might call Ms. Dawn Svoronos' independence into question. The shareholders' meeting also resolves that the mandate of Ms. Dawn Svoronos will be remunerated as provided for non-executive members of the Board of Directors in the Company's remuneration policy and as approved by the shareholders' meeting from time to time.

10. Appointment of Dr. Neil Johnston as independent non-executive director.

Proposed resolution: Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee, the shareholders' meeting resolves (a) to confirm the appointment by co-optation with effect as per November 1, 2025 (following the resignation of Dr. Elisabeth Svanberg, with effect as per the same date), and to appoint Dr. Neil Johnston as an independent non-executive member of the Board of Directors of the Company, for an additional period of two years, up to and including the closing of the annual shareholders' meeting to be held in 2028 which will have decided upon the financial statements for the financial year ended on December 31, 2027, and (b) to confirm his mandate as an independent member of the Board of

Directors, taking note of the fact that (i) the Board of Directors has determined that Dr. Neil Johnston meets the independence criteria set forth in article 7:87 of the Belgian Companies and Associations Code, and article 3.5 of the Belgian Corporate Governance Code 2020, (ii) Dr. Neil Johnston has explicitly declared not to have (and the Board of Directors is not aware of) any connections with the Company or a major shareholder, which would interfere with his independence, and (iii) the Board of Directors has no indication of any element that might call Dr. Neil Johnston's independence into question. The shareholders' meeting also resolves that the mandate of Dr. Neil Johnston will be remunerated as provided for non-executive members of the Board of Directors in the Company's remuneration policy and as approved by the shareholders' meeting from time to time.

11. Appointment of Mr. Devang Bhuva as non-executive director.

Proposed resolution: Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee, the shareholders' meeting resolves to confirm the appointment by co-optation with effect as per November 1, 2025 (following the resignation of Mr. Andrew Dickinson, with effect as per the same date), and to appoint Mr. Devang Bhuva as a non-executive member of the Board of Directors of the Company, for an additional period of three years, up to and including the closing of the annual shareholders' meeting to be held in 2029 which will have decided upon the financial statements for the financial year ended on December 31, 2028. The shareholders' meeting also resolves that the mandate of Mr. Devang Bhuva will not be remunerated.

12. Appointment of Dr. Paulo Fontoura as independent non-executive director.

Proposed resolution: Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee, the shareholders' meeting resolves (a) to confirm the appointment by co-optation with effect as per February 9, 2026 (following the resignation of Dr. Susanne Schaffert, with effect as per November 1, 2025), and to appoint Dr. Paulo Fontoura as an independent non-executive member of the Board of Directors of the Company, for an additional period of three years, up to and including the closing of the annual shareholders' meeting to be held in 2029 which will have decided upon the financial statements for the financial year ended on December 31, 2028, and (b) to confirm his mandate as an independent member of the Board of Directors, taking note of the fact that (i) the Board of Directors has determined that Dr. Paulo Fontoura meets the independence criteria set forth in article 7:87 of the Belgian Companies and Associations Code, and article 3.5 of the Belgian Corporate Governance Code 2020, (ii) Dr. Paulo Fontoura has explicitly declared not to have (and the Board of Directors is not aware of) any connections with the Company or a major shareholder, which would interfere with his independence, and (iii) the Board of Directors has no indication of any element that might call Dr. Paulo Fontoura's independence into question. The shareholders' meeting also resolves that the mandate of Dr. Paulo Fontoura will be remunerated as provided for non executive members of the Board of Directors in the Company's remuneration policy and as approved by the shareholders' meeting from time to time.

13. Appointment of Mr. Gino Santini as independent non-executive director.

Proposed resolution: Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee, the shareholders' meeting resolves to (a) appoint Mr. Gino Santini as independent non-executive member of the Board of Directors of the Company, for a period of four years, and with immediate effect, up to and including the closing of the annual shareholders' meeting to be held in 2030 which will have decided upon the financial statements for the financial year ended on December 31, 2029, and (b) to confirm his mandate as an independent member of the Board of Directors, taking note of the fact that (i) the Board of Directors has determined that Mr. Gino Santini meets the independence criteria set forth in article 7:87 of the Belgian Companies and Associations Code, and article 3.5 of the Belgian Corporate Governance Code 2020, (ii) Mr. Gino Santini has explicitly declared not to have (and the Board of Directors is not aware of) any connections with the Company or an important shareholder, which would interfere with his independence, and (iii) the Board of Directors has no indication of any element that might call Mr. Gino Santini's independence into question. The shareholders' meeting also resolves that the mandate of Mr. Gino Santini will be remunerated as provided for non-executive members of the Board of Directors in the Company's remuneration policy and as approved by the shareholders' meeting from time to time.

14. Re-appointment of statutory auditor and determination of statutory auditor's remuneration.

Proposed resolution: In accordance with the recommendation of the Audit Committee of the Board of Directors (hereinafter the "Audit Committee") and upon proposal of the Board of Directors, the shareholders' meeting resolves (a) to re-appoint BDO Bedrijfsrevisoren BV, with its registered office at Da Vincilaan 9/E.6, 1930 Zaventem, and registered with the Crossroads Bank for Enterprises (RPR Brussels, Dutch-speaking division) under the number 0431.088.289, permanently represented by Ellen Lombaerts, as statutory auditor of the Company for a period of three years ending immediately after the annual shareholders' meeting to be held in 2029 which will decide upon the Company's annual accounts for the financial year to be ended on December 31, 2028, and (b) to determine the annual remuneration of BDO Bedrijfsrevisoren BV for its mandate as statutory auditor of the Company at EUR 495,000 (if any, VAT exclusive) per year.

15. Confirmation and re-appointment of the statutory auditor with respect to the "assurance" of the CSRD sustainability reporting.

Proposed resolution: In accordance with the recommendation of the Audit Committee and upon proposal of the Board of Directors the shareholders' meeting resolves (a) as far as needed and required, to charge the Company's statutory auditor, being BDO Bedrijfsrevisoren BV, with its registered office at Da Vincilaan 9/E.6, 1930 Zaventem, and registered with the Crossroads Bank for Enterprises (RPR Brussels, Dutch-speaking division) under the number 0431.088.289, permanently represented by Ellen Lombaerts with the assurance of the sustainability reporting of the Company, as referred to in the CSRD, for a period of three years ending immediately after the annual shareholders' meeting to be held in 2029 which will decide upon the Company's annual accounts for the financial year to be ended on December 31, 2028, and (b) to determine the annual remuneration of BDO Bedrijfsrevisoren BV for the assurance of the Company's sustainability reporting at EUR 50,000 (if any, VAT exclusive) per year.

16. Remuneration of directors.

Proposed resolution: Upon recommendation and advice of the Remuneration Committee of the Board of Directors, the shareholders' meeting resolves that the annual compensation (excluding expenses) of the non-executive directors, other than the non-executive directors representing a shareholder, for the exercise of their mandate shall consist of a cash remuneration and an equity-based remuneration as follows:

(a) Cash remuneration: (i) Chairperson of the Board of Directors: EUR 110,000; (ii) Lead Non-Executive Director, if appointed in accordance with Galapagos' Corporate Governance Charter: EUR 75,000, (iii) other non-executive directors: EUR 55,000 each; (iv) additional annual compensation for the chairpersonship of a committee within the Board of Directors: EUR 20,000; and (v) additional annual compensation for the membership of a committee within the Board of Directors: EUR 15,000;

(b) Equity-based remuneration: (i) Chairperson of the Board of Directors: EUR 135,000; (ii) Lead Non-Executive Director, if appointed in accordance with Galapagos' Corporate Governance Charter: EUR 135,000; (iii) other non-executive directors: EUR 135,000 each; in each case (i), (ii) and (iii) subject to the requirement to use the net amount (after taxes) to acquire Galapagos shares. These latter payments make up the equivalent of an equity component of the directors' remuneration and the resulting shares are to be held until at least one year after the non-executive director leaves the Board of Directors and at least three years after the time of acquisition.

3. Convening to the meeting

3.1 Convening of the holders of dematerialized shares

In accordance with the Belgian Companies and Associations Code, the convening notice, mentioning the agenda and proposed resolutions, was issued by means of a press release published on the Company's website and through a press release circulated by GlobeNewswire on 26 March 2026, and through announcement on the website of Euronext on 27 March 2026.

Evidence of these publications is submitted to the meeting for review, and shall be kept at the registered office of the Company.

3.2 Publication via the website of the Company

The convening notice was also published on the Company's website on 26 March 2026. A printed copy of this publication is submitted to the meeting for review, and shall be kept at the registered office of the Company.

3.3 Convening of the holders of registered shares and registered subscription rights, the Board members and the statutory auditor

In accordance with the Belgian Companies and Associations Code, the convening notice, mentioning the agenda and proposed resolutions, was sent on 27 March 2026 by e-mail or letter to the holders of registered shares, the holders of registered subscription rights and the statutory auditor.

The Board members waived all notice periods and notice requirements in respect of this shareholders' meeting, as well as the right to receive the above-mentioned reports and documents, in accordance with articles 7:129 and 7:132 of the Belgian Companies and Associations Code and the articles referring thereto.

3.4 Communication to Euronext, FSMA and AFM

The Company is a listed company. The convening notice, mentioning the agenda and proposed resolutions, has therefore also been communicated to the Financial Services and Markets Authority ("FSMA"), to Euronext and to the Dutch Financial Markets Authority ("AFM"), by e-mail dated 27 March 2026. A printed copy of this e-mail is submitted to the meeting for review, and shall be kept at the registered office of the Company.

4. Right to add agenda items

The Secretary states that no requests of shareholders were received to add additional items to the agenda of the meeting or to submit proposed resolutions in relation to existing agenda items or new items to be added to the agenda.

5. Quorum

There is no attendance quorum requirement for the deliberation and voting on the items referred to in the agenda of this shareholders' meeting. Consequently, the meeting can validly deliberate and resolve, irrespective of the number of shares that are present and/or represented.

The capital of the Company is currently represented by 65,897,071 shares.

It appears from the attendance list that 49,182,761 shares (*i.e.* 76,64%) were present or represented.

6. Voting right – Majority

The Company has not issued shares without voting rights. Each share entitles to one vote. In order to be validly adopted, each proposed resolution needs to obtain a simple majority of the votes cast.

In accordance with article 25/1 of the Belgian Act of 2 May 2007 on the disclosure of significant shareholdings in issuers whose securities are admitted to trading on a regulated market and containing various provisions, as amended from time to time (the "**Belgian Transparency Act**"), no person can participate in the voting at the shareholders' meeting of the Company for more voting rights than those attached to the securities with respect to which such person has filed a notification in accordance with articles 6 and 7 of the Belgian Transparency Act *juncto* article 8 of the Company's articles of association at least 20 days prior to the date of the shareholders' meeting. Pursuant to article 8 of the articles of association of the Company, the relevant thresholds for a notification are 5%, 10%, 15%, 20% or any further multiple of 5% of the outstanding voting rights. For all of the shareholders present or represented, it is determined that they can participate with all of the shares that they have submitted.

Validity of the meeting

The meeting acknowledges the accuracy of the above statements, unanimously acknowledges that it is validly convened and composed, as well as capable to deliberate and, if applicable, to vote on the agenda items of this meeting, and resolves to start deliberating on the agenda.

Resolution, deliberation and voting

The meeting decides to deal with the agenda of the shareholders' meeting, and the Secretary proposes to the meeting to deliberate and, where required, vote on the following proposed resolutions:

First agenda item

Acknowledgement and discussion of (a) the annual report of the Board of Directors in relation to the non-consolidated and consolidated annual accounts of the Company for the financial year ended on December 31, 2025, and (b) the report of the statutory auditor in relation to the non-consolidated annual accounts of the Company for the financial year ended on December 31, 2025.

The Secretary submits the annual report of the Board of Directors in relation to the non-consolidated and consolidated annual accounts of the Company for the financial year ended on 31 December 2025. The Secretary also submits the report of the statutory auditor in relation to the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2025.

The Secretary asks the shareholders' meeting for exemption from reading out both reports. The meeting agrees to this.

The meeting takes note of and discusses (a) the annual report of the Board of Directors in relation to the non-consolidated and consolidated annual accounts of the Company for the financial year ended on 31 December 2025, and (b) the report of the statutory auditor in relation to the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2025.

There being no questions, the meeting proceeds to the next agenda item.

Second agenda item

Acknowledgement and approval of the non-consolidated annual accounts of the Company for the financial year ended on December 31, 2025, and approval of the allocation of the annual result as proposed by the Board of Directors.

The Secretary submits the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2025.

There being no questions, the meeting proceeds to vote on the proposed resolution.

The shareholders' meeting resolves to approve the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2025, and the allocation of the annual result as proposed by the Board of Directors.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761 representing 74,64% of the capital as at the opening of the meeting.

This resolution is adopted by the meeting with 45,027,705 votes (91.55%) in favor, 12,087 votes (0.02%) against and 4,142,969 abstentions (8.42%).

Third agenda item

Acknowledgement and discussion of the report of the statutory auditor relating to the consolidated annual accounts of the Company for the financial year ended on December 31, 2025.

The Secretary submits the report of the statutory auditor relating to the consolidated annual accounts of the Company for the financial year ended on 31 December 2025.

The Secretary asks the shareholders' meeting for exemption from reading out this report. The meeting agrees to this.

The meeting takes note of and discusses the report of the statutory auditor relating to the consolidated annual accounts of the Company for the financial year ended on 31 December 2025.

There being no questions, the meeting proceeds to the next agenda item.

Fourth agenda item

Acknowledgement and discussion of the consolidated annual accounts of the Company for the financial year ended on December 31, 2025.

The Secretary submits the consolidated annual accounts of the Company for the financial year ended on 31 December 2025.

The meeting takes note of and discusses the consolidated annual accounts of the Company for the financial year ended on 31 December 2025.

There being no questions, the meeting proceeds to the next agenda item.

Fifth agenda item

Acknowledgement and approval of the remuneration report.

The Secretary submits the remuneration report as included in the annual report of the Board of Directors for the financial year ended on 31 December 2025.

The Secretary asks the shareholders' meeting for exemption from reading out this report. The meeting agrees to this.

There being no questions, the meeting proceeds to vote on the proposed resolution.

The shareholders' meeting resolves to approve the remuneration report included in the annual report of the Board of Directors for the financial year ended on 31 December 2025.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761, representing 74,64% of the capital as at the opening of the meeting.

This resolution is adopted by the meeting with 37,386,843 votes (76.02%) in favor, 11,048,698 votes (22.46%) against and 747,220 abstentions (1.52%).

Sixth agenda item

Release from liability to be granted to the (current and former) members of the Board of Directors, and the statutory auditor for the performance of their respective mandates during the financial year ended on December 31, 2025.

There being no questions, the meeting proceeds to vote on the proposed resolution.

The shareholders' meeting resolves, by a separate vote, to release each (current and former) member of the Board of Directors, and the statutory auditor from any liability arising from the performance of their respective mandates during the financial year ended on 31 December 2025.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761 representing 74.64% of the capital as at the opening of the meeting.

This resolution is adopted by the meeting with 44,987,385 votes (91.47 %) in favor, 4,167,422 votes (8.47%) against and 27,954 abstentions (0.06%).

Seventh agenda item

Appointment of Mr. Henry Gosebruch as executive director.

There being no questions , the meeting proceeds to vote on the proposed resolution.

Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee of the Board of Directors (hereinafter the "Nomination Committee"), the shareholders' meeting resolves to confirm the appointment by co-optation with effect as per May 12, 2025 (following the resignation of Stoffels IMC BV, permanently represented by Mr. Paul Stoffels, with effect as per the same date) and to appoint Mr. Henry Gosebruch as an executive member of the Board of Directors of the Company, for an additional period of four years, up to and including the closing of the annual shareholders' meeting to be held in 2030 which will have decided upon the financial statements for the financial year ended on December 31, 2029. The shareholders' meeting also resolves that the mandate of Mr. Henry Gosebruch as a director of the Company will not be remunerated.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761, representing 74.64 % of the capital as at the opening of the meeting.

This resolution is adopted by the meeting with 44,816,329 votes (91.12%) in favor, 4,365,146 votes (8.88%) against and 1,286 abstentions (0.00 %).

Eighth agenda item

Appointment of Dr. Jane Griffiths as independent non-executive director.

There being no questions , the meeting proceeds to vote on the proposed resolution.

Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee, the shareholders' meeting resolves (a) to confirm the appointment by co-optation with effect as per July 28, 2025 (following the resignation of Mr. Simon Sturge, with effect as per the same date), and to appoint Dr. Jane Griffiths as an independent non-executive member of the Board of Directors of the Company, for an additional period of four years, up to and including the closing of the annual shareholders' meeting to be held in 2030 which will have decided upon the financial statements for the financial year ended on December 31, 2029, and (b) to confirm her mandate as an independent member of the Board of Directors, taking note of the fact that (i) the Board of Directors has determined that Dr. Jane Griffiths meets the independence criteria set forth in article 7:87 of the Belgian Companies and Associations Code, and article 3.5 of the Belgian Corporate Governance Code 2020, (ii) Dr. Jane Griffiths has explicitly declared not to have (and the Board of Directors is not aware of) any connections with the Company or a major shareholder, which would interfere with her independence, and (iii) the Board of Directors has no indication of any element that might call Dr. Jane Griffiths' independence into question. The shareholders' meeting also resolves that the mandate of Dr. Jane Griffiths will be remunerated as provided for non-executive members of the Board of Directors in the Company's remuneration policy and as approved by the shareholders' meeting from time to time.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761, representing 74.64 % of the capital as at the opening of the meeting.

This resolution is adopted by the meeting with 44,887,649 votes (91.27%) in favor, 4,293,189 votes (8.73%) against and 1,923 abstentions (0.00 %).

Ninth agenda item

Appointment of Ms. Dawn Svoronos as independent non-executive director.

There being no questions, the meeting proceeds to vote on the proposed resolution.

Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee, the shareholders' meeting resolves (a) to confirm the appointment by co-optation with effect as per July 28, 2025 (following the resignation of Mr. Peter Guenter, with effect as per the same date), and to appoint Ms. Dawn Svoronos as an independent non-executive member of the Board of Directors of the Company, for an additional period of four years, up to and including the closing of the annual shareholders' meeting to be held in 2030 which will have decided upon the financial statements for the financial year ended on December 31, 2029, and (b) to confirm her mandate as an independent member of the Board of Directors, taking note of the fact that (i) the Board of Directors has determined that Ms. Dawn Svoronos meets the independence criteria set forth in article 7:87 of the Belgian Companies and Associations Code, and article 3.5 of the Belgian Corporate Governance Code 2020, (ii) Ms. Dawn Svoronos has explicitly declared not to have (and the Board of Directors is not aware of) any connections with the Company or a major shareholder, which would interfere with her independence, and (iii) the Board of Directors has no indication of any element that might call Ms. Dawn Svoronos' independence into question. The shareholders' meeting also resolves that the mandate of Ms. Dawn Svoronos will be remunerated as provided for non-executive members of the Board of Directors in the Company's remuneration policy and as approved by the shareholders' meeting from time to time.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761, representing 74.64% of the capital as at the opening of the meeting.

This resolution is adopted by the meeting with 44,816,642 votes (91.12%) in favor, 4,364,826 votes (8.87 %) against and 1,293 abstentions (0.00%).

Tenth agenda item

Appointment of Dr. Neil Johnston as independent non-executive director.

There being no questions, the meeting proceeds to vote on the proposed resolution.

Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee, the shareholders' meeting resolves (a) to confirm the appointment by co-optation with effect as per November 1, 2025 (following the resignation of Dr. Elisabeth Svanberg, with effect as per the same date), and to appoint Dr. Neil Johnston as an independent non-executive member of the Board of Directors of the Company, for an additional period of two years, up to and including the closing of the annual shareholders' meeting to be held in 2028 which will have decided upon the financial statements for the financial year ended on December 31, 2027, and (b) to confirm his mandate as an independent member of the Board of Directors, taking note of the fact that (i) the Board of Directors has determined that Dr. Neil Johnston meets the independence criteria set forth in article 7:87 of the Belgian Companies and Associations Code, and article 3.5 of the Belgian Corporate Governance Code 2020, (ii) Dr. Neil Johnston has explicitly declared not to have (and the Board of Directors is not aware of) any connections with the Company or a major shareholder, which would interfere with his independence, and (iii) the Board of Directors has no indication of any element that might call Dr. Neil Johnston's independence into question. The shareholders' meeting also resolves that the mandate of Dr. Neil Johnston will be remunerated as provided for non-executive members of the Board of Directors in the Company's remuneration policy and as approved by the shareholders' meeting from time to time.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761, representing 74.64% of the capital as at the opening of the meeting.

This resolution is adopted by the meeting with 44,915,018 votes (91.32%) in favor, 4,265,621 votes (8.67%) against and 2,122 abstentions (0.00%).

Eleventh agenda item

Appointment of Mr. Devang Bhuva as non-executive director.

There being no questions, the meeting proceeds to vote on the proposed resolution.

Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee, the shareholders' meeting resolves to confirm the appointment by co-optation with effect as per November 1, 2025 (following the resignation of Mr. Andrew Dickinson, with effect as per the same date), and to appoint Mr. Devang Bhuva as a non-executive member of the Board of Directors of the Company, for an additional period of three years, up to and including the closing of the annual shareholders' meeting to be held in 2029 which will have decided upon the financial statements for the financial year ended on December 31, 2028. The shareholders' meeting also resolves that the mandate of Mr. Devang Bhuva will not be remunerated.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761, representing 74.64% of the capital as at the opening of the meeting.

This resolution is adopted by the meeting with 44,815,881 votes (91.12%) in favor, 4,364,934 votes (8.87%) against and 1,946 abstentions (0.00%).

Twelfth agenda item

Appointment of Dr. Paulo Fontoura as independent non-executive director.

There being no questions, the meeting proceeds to vote on the proposed resolution.

Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee, the shareholders' meeting resolves (a) to confirm the appointment by co-optation with effect as per February 9, 2026 (following the resignation of Dr. Susanne Schaffert, with effect as per November 1, 2025), and to appoint Dr. Paulo Fontoura as an independent non-executive member of the Board of Directors of the Company, for an additional period of three years, up to and including the closing of the annual shareholders' meeting to be held in 2029 which will have decided upon the financial statements for the financial year ended on December 31, 2028, and (b) to confirm his mandate as an independent member of the Board of Directors, taking note of the fact that (i) the Board of Directors has determined that

Dr. Paulo Fontoura meets the independence criteria set forth in article 7:87 of the Belgian Companies and Associations Code, and article 3.5 of the Belgian Corporate Governance Code 2020, (ii) Dr. Paulo Fontoura has explicitly declared not to have (and the Board of Directors is not aware of) any connections with the Company or a major shareholder, which would interfere with his independence, and (iii) the Board of Directors has no indication of any element that might call Dr. Paulo Fontoura's independence into question. The shareholders' meeting also resolves that the mandate of Dr. Paulo Fontoura will be remunerated as provided for non-executive members of the Board of Directors in the Company's remuneration policy and as approved by the shareholders' meeting from time to time.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761, representing 74.64% of the capital as at the opening of the meeting.

This resolution is adopted by the meeting with 44,946,911 votes (91.39%) in favor, 4,233,927 votes (8.61%) against and 1,923 abstentions (0.00%).

Thirteenth agenda item

Appointment of Mr. Gino Santini as independent non-executive director.

There being no questions, the meeting proceeds to vote on the proposed resolution.

Upon proposal of the Board of Directors, and in accordance with the recommendation and advice of the Nomination Committee, the shareholders' meeting resolves to (a) appoint Mr. Gino Santini as independent non-executive member of the Board of Directors of the Company, for a period of four years, and with immediate effect, up to and including the closing of the annual shareholders' meeting to be held in 2030 which will have decided upon the financial statements for the financial year ended on December 31, 2029, and (b) to confirm his mandate as an independent member of the Board of Directors, taking note of the fact that (i) the Board of Directors has determined that Mr. Gino Santini meets the independence criteria set forth in article 7:87 of the Belgian Companies and Associations Code, and article 3.5 of the Belgian Corporate Governance Code 2020, (ii) Mr. Gino Santini has explicitly declared not to have (and the Board of Directors is not aware of) any connections with the Company or an important shareholder, which would interfere with his independence, and (iii) the Board of Directors has no indication of any element that might call Mr. Gino Santini's independence into question. The shareholders' meeting also resolves that the mandate of Mr. Gino Santini will be remunerated as provided for non-executive members of the Board of Directors in the Company's remuneration policy and as approved by the shareholders' meeting from time to time.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761, representing 74.64% of the capital as at the opening of the meeting.

This resolution is adopted by the meeting with 40,883,062 votes (83.12%) in favor, 7,552,446 votes (15.36%) against and 747,253 abstentions (1.52%).

Fourteenth agenda item

Re-appointment of statutory auditor and determination of statutory auditor's remuneration.

There being no questions, the meeting proceeds to vote on the proposed resolution.

In accordance with the recommendation of the Audit Committee of the Board of Directors (hereinafter the "Audit Committee") and upon proposal of the Board of Directors, the shareholders' meeting resolves (a) to re-appoint BDO Bedrijfsrevisoren BV, with its registered office at Da Vincilaan 9/E.6, 1930 Zaventem, and registered with the Crossroads Bank for Enterprises (RPR Brussels, Dutch-speaking division) under the number 0431.088.289, permanently represented by Ellen Lombaerts, as statutory auditor of the Company for a period of three years ending immediately after the annual shareholders' meeting to be held in 2029 which will decide upon the Company's annual accounts for the financial year to be ended on December 31, 2028, and (b) to determine the annual remuneration of BDO Bedrijfsrevisoren BV for its mandate as statutory auditor of the Company at EUR 495,000 (if any, VAT exclusive) per year.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761, representing 74.64% of the capital as at the opening of the meeting.

This resolution is adopted by the meeting with 45,044,745 votes (91.59%) in favor, 8,361 votes (0.02%) against and 4,129,655 abstentions (8.40%).

Fifteenth agenda item

Confirmation and re-appointment of the statutory auditor with respect to the "assurance" of the CSRD sustainability reporting.

There being no questions, the meeting proceeds to vote on the proposed resolution.

In accordance with the recommendation of the Audit Committee and upon proposal of the Board of Directors the shareholders' meeting resolves (a) as far as needed and required, to charge the Company's statutory auditor, being BDO Bedrijfsrevisoren BV, with its registered office at Da Vincilaan 9/E.6, 1930 Zaventem, and registered with the Crossroads Bank for Enterprises (RPR Brussels, Dutch-speaking division) under the number 0431.088.289, permanently represented by Ellen Lombaerts with the assurance of the sustainability reporting of the Company, as referred to in the CSRD, for a period of three years ending immediately after the annual shareholders' meeting to be held in 2029 which will decide upon the Company's annual accounts for the financial year to be ended on December 31, 2028, and (b) to determine the annual remuneration of BDO Bedrijfsrevisoren BV for the assurance of the Company's sustainability reporting at EUR 50,000 (if any, VAT exclusive) per year.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761, representing 74.64% of the capital as at the opening of the meeting.

This resolution is adopted by the meeting with 45,043,541 votes (91.58%) in favor, 9,835 votes (0.02%) against and 4,129,385 abstentions (8.40%).

Sixteenth agenda item

Remuneration of directors.

There being no questions, the meeting proceeds to vote on the proposed resolution.

Upon recommendation and advice of the Remuneration Committee of the Board of Directors, the shareholders' meeting resolves that the annual compensation (excluding expenses) of the non-executive directors, other than the non-executive directors representing a shareholder, for the exercise of their mandate shall consist of a cash remuneration and an equity-based remuneration as follows:

(a) Cash remuneration: (i) Chairperson of the Board of Directors: EUR 110,000; (ii) Lead Non-Executive Director, if appointed in accordance with Galapagos' Corporate Governance Charter: EUR 75,000, (iii) other non-executive directors: EUR 55,000 each; (iv) additional annual compensation for the chairpersonship of a committee within the Board of Directors: EUR 20,000; and (v) additional annual compensation for the membership of a committee within the Board of Directors: EUR 15,000;

(b) Equity-based remuneration: (i) Chairperson of the Board of Directors: EUR 135,000; (ii) Lead Non-Executive Director, if appointed in accordance with Galapagos' Corporate Governance Charter: EUR 135,000; (iii) other non-executive directors: EUR 135,000 each; in each case (i), (ii) and (iii) subject to the requirement to use the net amount (after taxes) to acquire Galapagos shares. These latter payments make up the equivalent of an equity component of the directors' remuneration and the resulting shares are to be held until at least one year after the non-executive director leaves the Board of Directors and at least three years after the time of acquisition. The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761, representing 74.64% of the capital as at the opening of the meeting.

The shareholders' meeting resolves that the mandate of a non-executive director representing a shareholder will not be remunerated. The rules set out above shall apply as from May 1, 2026.

The total number of shares for which a vote was validly issued for this resolution equals the number of validly issued votes, and amounts to 49,182,761, representing 74.64% of the capital as at the opening of the meeting.

This resolution is adopted by the meeting with 44,931,012 votes (91.36%) in favor, 4,249,460 votes (8.64%) against and 2,289 abstentions (0.00%).

Closing

The agenda of this meeting is finished, and the meeting is closed by the Chairman at 3.05 p.m. CEST.

Of which these minutes were drawn up.

Made on the date and place as set forth above.

The Chairman asks the shareholders' meeting for exemption from reading out these minutes. The meeting agrees to this. Subsequently, the members of the bureau and the members of the meeting who so desired, signed these minutes.

[signed]	[signed]	[signed]
J. Contamine Chairman	H. Gosebruch Director	J. Griffiths Director
[signed]	[signed]	[signed]
F. Lecoutre Secretary	A. Denecker Teller	E. Van Mol Teller